v3.26.3
STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY (Tables)
9 Months Ended
Aug. 31, 2026
STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY  
Schedule of continuity of stock options and stock options outstanding and exercisable

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

​

  ​ ​ ​

Weighted average

  ​ ​ ​ ​

Weighted average

​

​

Number of stock options

​

exercise price

 

remaining life (years)

Outstanding, November 30, 2025

 

—

​

$

—

​

—

Granted

 

887,375

​

 

9.87

​

—

Outstanding, August 31, 2026

​

887,375

​

$

9.87

​

4.63

Exercisable, August 31, 2026

 

307,251

​

$

9.84

​

4.64

Schedule of continuity of RSUs

​

​

​

​

​

​

​

​

  ​ ​ ​

​

  ​ ​ ​

Weighted average grant

​

​

Number of RSUs

​

date fair value

Unvested, November 30, 2025

​

—

​

​

—

Granted

​

592,125

​

$

9.31

Vested

​

(231,751)

​

​

9.28

Unvested, August 31, 2026

​

360,374

​

$

9.32

Schedule of warrants activity

As of August 31, 2026, the continuity of share purchase warrants is as follows:

​

​

​

​

​

​

​

​

​

​

Number of

​

Weighted Average

​

Remaining

​

  ​ ​ ​

warrants

  ​ ​ ​

Exercise price

  ​ ​ ​

life (Years)

Balance, November 30, 2025

​

—

​

$

—

​

—

Issued for PIPE financing

​

2,500,000

​

​

12.00

​

—

Issued on reverse recapitalization (Note 3)

​

20,922,133

​

​

11.50

​

—

Exercised

 

(200)

 

 

11.50

 

—

Adjustment

 

(17)

 

 

11.50

 

—

Balance, August 31, 2026

​

23,421,916

​

$

11.55

​

4.49

Exercisable, August 31, 2026

 

23,421,916

 

$ 

11.55

 

4.49

​

Black-Scholes  
STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY  
Schedule of company determined that stock options had a fair value

​

​

​

​

​

Expected volatility

  ​ ​ ​

114.01

%

Expected term

 

2.75 years – 3 years

​

Risk free interest rate

 

3.99

%

Dividend yield

 

0

%

Monte Carlo Pricing Model  
STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY  
Schedule of company determined that stock options had a fair value

​

​

​

​

​

Expected volatility

  ​ ​ ​

120.0

%

Contractual term to expiry

 

5 years

​

Risk free interest rate

 

3.83

%

Early exercise price hurdle

 

2.5x

​

Common stock, subject to possible redemption  
STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY  
Schedule of redeemable common stock

​

Redeemable common stock, November 30, 2025

  ​ ​ ​

$

300,000

Less: transfer to permanent equity

 

​

(300,000)

Redeemable common stock, August 31, 2026

​

$

—

Series A cumulative preferred stock, redeemable  
STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY  
Schedule of redeemable common stock

​

Redeemable Series A Cumulative Convertible Preferred Stock, November 30, 2025

  ​ ​ ​

$

—

Gross proceeds

​

​

29,700,000

Allocation to warrant liability (Note 8)

 

​

(4,174,276)

Accretion

 

​

401,171

Dividends paid-in-kind

​

​

937,381

Redeemable Series A Cumulative Convertible Preferred Stock, August 31, 2026

​

$

26,864,276